The circumstance and manner of death are numbing:farmers hacked and mutilated by machetes,dragged to death behind vehicles,stabbed with farm tools,shot execution style,and more—much more. The death toll of white farmers murdered in ...
Tags: farmers, murder, poverty, robbery motives
Advanced Biological Laboratories (ABL) has received CE mark approval for its DeepChek and ViroScore Suite clinical genotyping solutions. The approval is based on several evaluations of the company's next generation sequencing (NGS) ...
Tags: Advanced Biological, ABL, CE mark approval, evaluations
The Antiviral Drugs Advisory Committee of the FDA has recommended the approval of Gilead's Quad to treat HIV-1 infection in treatment-naive adults. The Quad is a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine ...
Tags: gilead's quad, HIV-1, quad NDA
Gilead Sciences Truvada (emtricitabine and tenofovir disoproxil fumarate) has received approval from the US Food and Drug Administration (FDA). Truvada is the first agent to get approval for HIV prevention in uninfected adults, a strategy ...
Tags: HIV testing, Truvada, PrEP, pre-exposure prophylaxis
Gilead Sciences has received US Food and Drug Administration (FDA) approval for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Stribild is a complete once-daily single tablet ...
Roche has gained FDA approval for the new HIV viral load test, the COBAS TaqMan HIV-1 Test, v2.0, and will launch the product in the US, later in 2012. The COBAS TaqMan HIV-1 Test, v2.0, targets two highly conserved regions of the HIV-1 ...
ICF International (ICFI), a technology service provider, has received a $5m re-compete contract from the US Department of Health and Human Services (HHS) to provide assistance to the Office of the Assistant Secretary for Health Regional ...
Tags: ICF International, ICFI, sexually transmitted infection, HIV/AIDS
Religare Health Insurance (RHICL) has formally launched its general insurance operations with head office in Delhi, India, as part of its business initiations in July 2012. Religare Health Insurance MD &CEO Anuj Gulati said, "Given our ...
Tags: Health Insurance, insurance operations, insurance firm, insurance
CytoDyn has entered into an agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140, for $3.5m. Upon successful continued clinical development of PRO ...
Tags: CytoDyn, HIV viral-entry inhibitor drug, humanized monoclonal antibody
Theravectys has received regulatory clearances from France's National Security Agency and Belgium's Federal Agency for Medicines and Health Products to commence a phase I/II clinical trial of its anti-HIV therapeutic vaccine. Using the ...
Tags: Theravectys, HIV positive patients, anti-HIV therapeutic vaccine
Mylan Pharmaceuticals has gained final FDA approval for its abbreviated new drug application (ANDA) for Nevirapine Tablets USP, 200mg and initiated the shipment of the product. The generic version of Boehringer Ingelheim's Viramune is ...
Tags: Mylan pharmaceuticals, ANDA, ARV
Helena Helmersson, Head of Sustainability for Hennes & Mauritz AB (H&M) announces that H&M is extending its All for Children collaboration with UNICEF, the United Nations Children's Fund, to include Bangladesh. In total H&M will contribute ...
Tags: UNICEF, donation, all for children project, Bangladesh
Sweden based Karolinska Institutet and Immunomedics scientists have collaborated to design and test new class of drugs that destroy the AIDS virus, HIV (Human Immunodeficiency Virus), which may also help in eliminating the virus completely. ...
Tags: Immunomedics, anti-HIV agents, virus
Ferrer Internacional has decided to withdraw the marketing authorisation application (MAA) for Egrifta (tesamorelin) 2mg, powder for solution for injection in Europe. Ferrer formally notified the European Medicines Agency of its decision. ...
Tags: DME, healthcare products, pSivida
Novara Therapeutics, an antiviral drug discovery company, has secured $23m in Series A financing to support the development of capsid-targeting antivirals to treat chronic hepatitis B (HBV) and HIV infections. The company's antiviral ...
Tags: antiviral drug discovery company, chronic hepatitis, HIV infections